GlassScriptPhysician profile
Ross B Reule
NPI 1811125529
$9,236.24
in general payments reported to CMS, 2019-2025
39 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $535 · 2021: $1,164 · 2022: $1,745 · 2023: $1,690 · 2024: $1,412 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,137 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,136.53 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.76 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $686.87 | 2019-2025 | Blu-U, Ilumya, Winlevi |
| Mayne Pharma Commercial LLC | $635.12 | 2020-2025 | |
| Janssen Biotech, INC. | $604.43 | 2019-2024 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $604.14 | 2019-2025 | |
| Lilly USA, LLC | $591.94 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $401.02 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $363.55 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $351.97 | 2019-2024 | Dupixent |
| Pfizer INC. | $294.59 | 2019-2025 | |
| Genzyme Corporation | $279.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $250.48 | 2022-2025 | Sotyktu |
| Almirall LLC | $249.10 | 2019-2025 | Seysara |
| Incyte Corporation | $232.91 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $231.46 | 2022-2024 | Vtama |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Reule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.